
Biotia provides clinicians and researchers fast, precise identification of infectious agents to guide diagnosis and treatment. The company combines next-generation sequencing with machine learning-powered analysis and laboratory workflows to detect and characterize pathogens. Biotia offers software and laboratory technology as a health‑tech solution, positioned as B2B SaaS and lab services for hospitals, public health labs, and research institutions. Its platform supports clinical decision-making and infectious disease surveillance by turning sequencing data into actionable results for care teams and researchers.

Biotia provides clinicians and researchers fast, precise identification of infectious agents to guide diagnosis and treatment. The company combines next-generation sequencing with machine learning-powered analysis and laboratory workflows to detect and characterize pathogens. Biotia offers software and laboratory technology as a health‑tech solution, positioned as B2B SaaS and lab services for hospitals, public health labs, and research institutions. Its platform supports clinical decision-making and infectious disease surveillance by turning sequencing data into actionable results for care teams and researchers.
What they do: Genomics + AI infectious‑disease diagnostics (software + CLIA lab services)
Headquarters / origin: Long Island City, New York; spinout from Jacobs Technion–Cornell Institute (Cornell Tech)
Founded: 2016
Notable products: BIOTIA‑ID, BIOTIA‑DX, GeoSeeq
Funding highlights: $2.4M seed (2019); $8M Series A (2022); total reported funding $10.7M
Infectious disease diagnostics and surveillance using genomic sequencing and AI.
2016
Biotechnology Research
2400000
Oversubscribed seed round announced by the company
8000000
Oversubscribed Series A announced by the company
Selected/awarded funding tied to Humans in Space / space‑health collaboration (reported as award/grant)
“Backed by a mix of institutional and angel investors including OCA Ventures, Continuum Health Ventures, SeedtoB Capital, SK Square Americas, Digital‑Dx Ventures, Falcon III/Falcon II family investors, and others (company lists a broad investor roster).”
| Company |
|---|